Business Wire

Philip Morris International Releases First TCFD Report, Recognized as Supplier Engagement Leader by CDP

Share

As Philip Morris International Inc. (PMI) (NYSE: PM) strives to remain at the forefront of a fast-evolving environmental, social, and governance (ESG) reporting landscape, the company today released its first-ever TCFD Report to respond to the implementation guidance of the Task Force on Climate-related Financial Disclosures (TCFD). The report’s findings were informed by a structured Climate Change Risk and Opportunity (CCRO) assessment that PMI conducted in 2022, with guidance from an external expert organization and in line with TCFD’s recommendations, to identify relevant climate-related risks and opportunities.

“Stakeholder expectations of businesses are shifting, and regulatory developments are moving forward at pace,” explained Emmanuel Babeau, Chief Financial Officer. “Companies are expected to demonstrate commendable behavior and transparency, providing trustworthy information on their impacts along the value chain and meeting mandatory reporting requirements in a range of jurisdictions. Accordingly, PMI continues to promote transparency by reporting against the most relevant and widely used sustainability standards.”

“For a business like ours—with a diversified agricultural supply chain that is sensitive to climate change—abrupt climate variations can endanger physical infrastructure and supply chains,” said Scott Coutts, Senior Vice President, Operations. “However, addressing the global challenge of climate change also presents opportunities. To realize these opportunities, PMI, alongside many of our suppliers, is working within a global context which is aiming to stabilize the global temperature rise to below the internationally agreed 1.5°C scenario. We understand the potential impacts of climate change across all areas of our operations, particularly upstream in our supply chain.”

PMI has been a supporter of the TCFD since 2021. In recent years, various elements of the company’s publicly available disclosure—such as its annual Integrated Report, CDP Climate disclosure, or annual report on Form10-K—already aligned with much of TCFD’s recommendations. Building on its CCRO assessment completed in 2022, PMI’s TCFD Report now compiles relevant information in one place and will continue to strengthen the company’s capacity to mitigate climate-related risks.

“We are proud to publish this report, which presents how we are implementing TCFD’s recommendations. It outlines the progress made to date toward our goal of incorporating climate-related risk and opportunity identification and management into our overall business strategy and disclosure efforts,” said Jennifer Motles, Chief Sustainability Officer. “It complements our Low-Carbon Transition Plan, published in 2021, which provides a transparent and detailed view on how we plan to achieve our climate ambitions, measure success, and report on progress, as we adapt our business model to succeed in a net-zero carbon economy.”

PMI’s strategies to Tackle Climate Change and Preserve Nature have been recognized by CDP, a not-for-profit charity that runs a global disclosure system for investors, companies, cities, and regions to manage their environmental impacts. In March 2023 and for the sixth consecutive year, PMI was included in CDP’s Supplier Engagement Leaderboard, distinguishing it as a global leader for engaging with suppliers on climate change and recognizing the effort PMI has put toward decarbonization, a key component in achieving its scope 3 ambitions. Additionally, in December 2022, for the third successive year, CDP awarded PMI the prestigious “Triple A” rating for the company’s performance in tackling climate change, protecting forests, and ensuring water security—placing it among the world’s most pioneering companies in environmental transparency and performance.

Earlier this month, PMI published its fourth annual Integrated Report 2022, which aims to provide an objective description of the company’s business model, strategy, performance, governance, and prospects in relation to its priority economic and ESG topics. To access PMI’s latest reports, as well as additional information on its approach to sustainability, please visit pmi.com/sustainability.

Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested more than USD 10.5 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, PMI acquired Swedish Match—a leader in oral nicotine delivery—creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration (FDA) has authorized versions of PMI’s IQOS Platform 1 devices and consumables and Swedish Match’s General snus as modified risk tobacco products (MRTPs). As of December 31, 2022, PMI’s smoke-free products were available for sale in 73 markets, and PMI estimates that approximately 17.8 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products accounted for approximately 32% of PMI’s total full-year 2022 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma subsidiary, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

David Fraser
Philip Morris International
+41 (0)58 242 4500
david.fraser@pmi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release

I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye